Citi lowered the firm’s price target on Baxter to $45 from $47 and keeps a Neutral rating on the shares. The analyst adjusted price targets in the medical technology space post the Q2 reports.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BAX:
- Baxter put volume heavy and directionally bearish
- Baxter price target lowered to $54 from $58 at Barclays
- Baxter price target lowered to $44 from $46 at Wells Fargo
- Baxter (NYSE:BAX) Stock Falls on Mixed Q2 Results, Guidance Trim
- Baxter sees FY23 adjusted EPS $2.87-$2,95, consensus $2.93
Questions or Comments about the article? Write to editor@tipranks.com